International Stem Cell is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the formation of pluripotent human stem cells from unfertilized oocytes (eggs) therefore avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line. For more information, visit the company’s Web site at www.internationalstemcell.com.

Let us hear your thoughts below: